Sugi Predict

Sugi Predict / Compounds / SCHEMBL1709926

SCHEMBL1709926

SCHEMBL1709926

CC1(C)Oc2ccc(Nc3nc(N4CCC(O)CC4)c4occc4n3)cc2NC1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 16/20 0.58
▸ TNK2 Q07912 3/20 0.40
▸ JAK2 O60674 2/20 0.40
▸ STK16 O75716 2/20 0.40
▸ ABL1 P00519 2/20 0.40
▸ LCK P06239 2/20 0.40
▸ FYN P06241 2/20 0.40
▸ RET P07949 2/20 0.40
▸ LTK P29376 2/20 0.40
▸ KDR P35968 2/20 0.40
▸ MAPK8 P45983 2/20 0.40
▸ PTK2 Q05397 2/20 0.40
▸ MAP4K2 Q12851 2/20 0.40
▸ AURKA O14965 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ INSR P06213 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1709927 0.95 SYK (0.57) SYKTNK2JAK2STK16ABL1
SCHEMBL1709883 0.91 SYK (0.56) SYKTNK2JAK2STK16ABL1
SCHEMBL3710851 0.90 SYK (0.58) SYKTNK2JAK2STK16ABL1
SCHEMBL1709819 0.90 SYK (0.58) SYKTNK2JAK2STK16ABL1
SCHEMBL3704837 0.90 SYK (0.58) SYKTNK2JAK2STK16ABL1
SCHEMBL1709852 0.90 SYK (0.56) SYKTNK2JAK2STK16ABL1
SCHEMBL3705242 0.89 SYK (0.59) SYKTNK2JAK2STK16ABL1
SCHEMBL3711504 0.89 SYK (0.55) SYKTNK2JAK2STK16ABL1
SCHEMBL3702259 0.88 SYK (0.53) SYKTNK2JAK2STK16ABL1
SCHEMBL3702255 0.88 SYK (0.55) SYKTNK2JAK2STK16ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885TNK2 429/4885JAK2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.